Evvy Raises $40 Million to Unlock Vaginal Microbiome Secrets for Better Women's Health

Women's health startup Evvy has secured $40 million in fresh funding to expand its work on vaginal microbiome data.

The Series B round was led by Catalio Capital Management and supports the company's mission to improve research and care for female-specific health issues.

Building on Years of Vaginal Health Innovation

Founded in 2021, Evvy offers an at-home test that uses advanced sequencing to analyze vaginal microbes with a single swab mailed to its lab.

Results include clinical interpretations and personalized next steps for users through a secure online portal.

The company has already served more than 100,000 patients and partnered with 3,000 practitioners while producing 15 peer-reviewed publications.

This data collection helps identify new bacterial subtypes and genomes that were previously unknown in science.

Why Microbiome Data Could Transform Everyday Lives

Evvy is now entering the fertility space by linking microbiome patterns to issues like infertility and pregnancy outcomes through ongoing studies.

Better data on female biology can address long-standing gaps in precision medicine where traditional datasets have overlooked women's unique needs.

In the future this approach may lead to earlier detection of conditions and more targeted treatments that reduce unexplained symptoms for many women.

Everyday people benefit because improved insights could lower healthcare costs and empower patients with actionable information at home.

Overall the funding signals growing investor interest in closing research gaps that have historically affected half the population.